AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Cancer cachexia is a multifactorial syndrome characterized by progressive weight loss and a disease process that nutritional support cannot reverse. Although progress has been made in preclinical research, there is still a long way to go in translating research findings into clinical practice. One of the main reasons for this is that existing preclinical models do not fully replicate the conditions seen in clinical patients. Therefore, it is important to understand the characteristics of existing preclinical models of cancer cachexia and pay close attention to the latest developments in preclinical models. The main models of cancer cachexia used in current research are allogeneic and xenograft models, genetically engineered mouse models, chemotherapy drug-induced models, Chinese medicine spleen deficiency models, zebrafish and Drosophila models, and cellular models. This review aims to revisit and summarize the commonly used animal models of cancer cachexia by evaluating existing preclinical models, to provide tools and support for translational medicine research.
Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365(6):565-567.
Blum D, Stene GB, Solheim TS, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model – a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol. 2014;25(8):1635-1642.
von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2016;7(5):507-509.
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-495.
Le-Rademacher JG, Crawford J, Evans WJ, Jatoi A. Overcoming obstacles in the design of cancer anorexia/weight loss trials. Crit Rev Oncol Hematol. 2017;117:30-37.
Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12(1):14-16.
Mueller TC, Bachmann J, Prokopchuk O, Friess H, Martni ME. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia-can findings from animal models be translated to humans? BMC Cancer. 2016;16:75.
Suzuki T, Von Haehling S, Springer J. Promising models for cancer-induced cachexia drug discovery. Expert Opin Drug Discov. 2020;15(5):627-637.
Ballaro R, Costelli P, Penna F. Animal models for cancer cachexia. Curr Opin Support Palliat Care. 2016;10(4):281-287.
Toledo M, Busquets S, Penna F, et al. Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type Ⅱ receptor inhibition and β-2 agonist. Int J Cancer. 2016;138(8):2021-2029.
Brown JL, Rosa-Caldwell ME, Lee DE, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2017;8(6):926-938.
Bonetto A, Rupert JE, Barreto R, Zimmers TA. The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J Vis Exp. 2016:117.
Neyroud D, Nosacka RL, Judge AR, Hepple RT. Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content. J Muscle Res Cell Motil. 2019;40(1):59-65.
Beck SA, Tisdale MJ. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer. 1990;62(3):420-424.
Miyaguti N, Chiocchetti GME, Salgado CM, et al. Walker-256 tumour-induced cachexia altered liver metabolomic profile and function in weanling and adult rats. Metabolites. 2021;11(12).
Pötsch MS, Ishida J, Palus S, et al. MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. J Cachexia Sarcopenia Muscle. 2020;11(2):594-605.
García-Martínez C, López-Soriano FJ, Argilés JM. Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett. 1994;87(2):123-130.
Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3(1):31-36.
Costelli P, Carbó N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92(6):2783-2789.
Brown JL, Lee DE, Rosa-Caldwell ME, et al. Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2018;9(5):987-1002.
Bennani-Baiti N, Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Support Care Cancer. 2011;19(9):1451-1463.
Penna F, Busquets S, Argiles JM. Experimental cancer cachexia: evolving strategies for getting closer to the human scenario. Semin Cell Dev Biol. 2016;54:20-27.
Matsuyama T, Ishikawa T, Okayama T, et al. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int J Cancer. 2015;137(11):2558-2565.
Norden DM, Devine R, McCarthy DO, Wold LE. Storage conditions and Passages Alter IL-6 secretion in C26 adenocarcinoma cell lines. MethodsX. 2015;2:53-58.
Dwarkasing JT, Boekschoten MV, Argiles JM, et al. Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling. J Cachexia Sarcopenia Muscle. 2015;6(1):84-94.
Pin F, Novinger LJ, Huot JR, et al. PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 2019;33(6):7778-7790.
Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012;303(3):E410-E421.
Seto DN, Kandarian SC, Jackman RW. A key role for leukemia inhibitory factor in C26 cancer cachexia. J Biol Chem. 2015;290(32):19976-19986.
Kandarian SC, Nosacka RL, Delitto AE, et al. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2018;9(6):1109-1120.
Ando K, Takahashi F, Kato M, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One. 2014;9(7):e102436.
Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013;31(6):e69-e72.
Niu M, Song S, Su Z, et al. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice. Br J Pharmacol. 2021;178(22):4485-4500.
Talbert EE, Cuitiño MC, Ladner KJ, et al. Modeling human cancer-induced cachexia. Cell Rep. 2019;28(6):1612-1622.e4.
de Fatima Silva F, de Morais H, Ortiz Silva M, et al. Akt activation by insulin treatment attenuates cachexia in Walker-256 tumor-bearing rats. J Cell Biochem. 2020;121(11):4558-4568.
Beluzi M, Peres SB, Henriques FS, et al. Pioglitazone treatment increases survival and prevents body weight loss in tumor-bearing animals: possible anti-cachectic effect. PLoS One. 2015;10(3):e0122660.
Pizato N, Bonatto S, Yamazaki RK, et al. Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats. Nutr Cancer. 2005;53(2):194-201.
Tessitore L, Bonelli G, Baccino FM. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. Biochem J. 1987;241(1):153-159.
Tanaka M, Sugimoto K, Fujimoto T, et al. Differential effects of pre-exercise on cancer cachexia-induced muscle atrophy in fast- and slow-twitch muscles. FASEB J. 2020;34(11):14389-14406.
Pototschnig I, Feiler U, Diwoky C, et al. Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia. J Cachexia Sarcopenia Muscle. 2023;14(1):93-107.
Inoue T, Terada N, Kobayashi T, Ogawa O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol. 2017;14(5):267-283.
Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathol Microbiol Scand. 1969;77(4):758-760.
Sun FX, Tang ZY, Lui KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996;66(2):239-243.
Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12(7):473-480.
Pin F, Barreto R, Kitase Y, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685-700.
Lerner L, Tao J, Liu Q, et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle. 2016;7(4):467-482.
Bernardo B, Joaquim S, Garren J, et al. Characterization of cachexia in the human fibrosarcoma HT-1080 mouse tumour model. J Cachexia Sarcopenia Muscle. 2020;11(6):1813-1829.
Invrea F, Rovito R, Torchiaro E, Petti C, Isella C, Medico E. Patient-derived xenografts (PDXs) as model systems for human cancer. Curr Opin Biotechnol. 2020;63:151-156.
Gerber MH, Underwood PW, Judge SM, et al. Local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine. Int J Mol Sci. 2018;19(12).
Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247(4940):322-324.
Puppa MJ, White JP, Sato S, Cairns M, Baynes JW. Carson JA.Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta. 2011;1812(12):1601-1606.
Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256(5057):668-670.
Baltgalvis KA, Berger FG, Peña MM, Davis JM, White JP, Carson JA. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc (Min/+) mouse. Pflugers Arch. 2009;457(5):989-1001.
Hardee JP, Counts BR, Gao S, et al. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle. 2018;9(2):369-383.
Campos CA, Bowen AJ, Han S, Wisse BE, Palmiter RD, Schwartz MW. Cancer-induced anorexia and malaise are mediated by CGRP neurons in the parabrachial nucleus. Nat Neurosci. 2017;20(7):934-942.
Martin A, Castells J, Allibert V, et al. Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice. J Cachexia Sarcopenia Muscle. 2022;13(3):1686-1703.
Zhang B, Bi Q, Huang S, et al. Baoyuan Jiedu decoction alleviating cancer cachexia-Induced muscle atrophy by regulating muscle mitochondrial function in Apc (Min/+) mice. Front Pharmacol. 2022;13:914597.
Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Curr Protoc Pharmacol. 2016;73:14.39.11-14.39.20.
Ashizawa S, Brunicardi FC, Wang XP. PDX-1 and the pancreas. Pancreas. 2004;28(2):109-120.
Michaelis KA, Zhu X, Burfeind KG, et al. Establishment and characterization of a novel murine model of pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle. 2017;8(5):824-838.
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-1117.
Erdem M, Möckel D, Jumpertz S, et al. Macrophages protect against loss of adipose tissue during cancer cachexia. J Cachexia Sarcopenia Muscle. 2019;10(5):1128-1142.
Dubois N, Bennoun M, Allemand I, et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol. 1991;13(2):227-239.
Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol. 2003;38(6):793-802.
Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014;20(3):433-447.
Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene. 2000;19(23):2739-2744.
Luan Y, Zhang Y, Yu SY, et al. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study. J Cachexia Sarcopenia Muscle. 2022;13(2):1289-1301.
Kim SY, Ebbert K, Cordeiro MH, et al. Cell autonomous phosphoinositide 3-kinase activation in oocytes disrupts normal ovarian function through promoting survival and overgrowth of ovarian follicles. Endocrinology. 2015;156(4):1464-1476.
Zhou Z, Ren Y, Yang J, et al. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Gastroenterology. 2022;163(5):1281-1293. e1281.
Olson B, Zhu X, Norgard MA, et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat Commun. 2021;12(1):2057.
Lemecha M, Chalise JP, Takamuku Y, et al. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia. Mol Metab. 2022;66:101612.
Meng X, Huang Z, Inoue A, et al. activity controls cachexia-induced muscle atrophy via the modulation of IRS1 ubiquitination. J Cachexia Sarcopenia Muscle. 2022;13(2):1197-1209.
Hain BA, Xu H, VanCleave AM, Gordon BS, Kimball SR, Waning DL. REDD1 deletion attenuates cancer cachexia in mice. J Appl Physiol (1985). 2021;131(6):1718-1730.
Sadek J, Hall DT, Colalillo B, et al. Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects. EMBO Mol Med. 2021;13(7):e13591.
Campelj DG, Goodman CA, Rybalka E. Chemotherapy-induced myopathy: the dark side of the cachexia sphere. Cancers. 2021;13(14).
Chen JA, Splenser A, Guillory B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6(2):132-143.
Coletti D. Chemotherapy-induced muscle wasting: an update. Eur J Transl Myol. 2018;28(2):7587.
Berardi E, et al. A pound of flesh: what cachexia is and what it is not. Diagnostics. 2021;11(1):116.
Campelj DG, Debruin DA, Timpani CA, Hayes A, Goodman CA, Rybalka E. Sodium nitrate co-supplementation does not exacerbate low dose metronomic doxorubicin-induced cachexia in healthy mice. Sci Rep. 2020;10(1):15044.
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265-7279.
Brierley DI, Harman JR, Giallourou N, et al. Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol. J Cachexia Sarcopenia Muscle. 2019;10(4):844-859.
Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-338.
Barreto R, Waning DL, Gao H, Liu Y, Zimmers TA, Bonetto A. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 2016;7(28):43442-43460.
Barreto R, Kitase Y, Matsumoto T, et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep. 2017;7(1):14470.
Barreto R, Mandili G, Witzmann FA, Novelli F, Zimmers TA, Bonetto A. Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Front Physiol. 2016;7:472.
O’Connell TM, Pin F, Couch ME, Bonetto A. Treatment with Soluble Activin Receptor Type ⅡB Alters Metabolic Response in Chemotherapy-Induced Cachexia. Cancers (Basel). 2019;11(9):1222.
Pin F, Barreto R, Couch ME, Bonetto A, O’Connell TM. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J Cachexia Sarcopenia Muscle. 2019;10(1):140-154.
Zhang WL, Li N, Shen Q, et al. Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I. Acta Pharmacol Sin. 2020;41(2):237-248.
Yang Q, Yan C, Wang X, Gong Z. Leptin induces muscle wasting in a zebrafish kras-driven hepatocellular carcinoma (HCC) model. Dis Model Mech. 2019;12(2):dmm038240.
Fei F, Sun S, Li Q, et al. Combinatorial Normalization of Liver-Derived Cytokine Pathways Alleviates Hepatic Tumor-Associated Cachexia in Zebrafish. Cancer Res. 2021;81(4):873-884.
Li Z, Huang X, Zhan H, et al. Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. J Hepatol. 2012;56(2):419-425.
Montal E, White RM. Zebrafish as a new model to study the crosstalk between tumor and host metabolism. Trends Cancer. 2021;7(8):661-663.
Naser FJ, Jackstadt MM, Fowle-Grider R, et al. Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. Cell Metab. 2021;33(7):1493-1504.e5.
Li Y, Lee AQ, Lu Z, et al. Systematic Characterization of the Disruption of Intestine during Liver Tumor Progression in the xmrk Oncogene Transgenic Zebrafish Model. Cells. 2022;11(11):1810.
Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005;6(1):9-23.
Kwon Y, Song W, Droujinine IA, Hu Y, Asara JM, Perrimon N. Systemic organ wasting induced by localized expression of the secreted insulin/IGF antagonist ImpL2. Dev Cell. 2015;33(1):36-46.
Figueroa-Clarevega A, Bilder D. Malignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting. Dev Cell. 2015;33(1):47-55.
Ding G, Xiang X, Hu Y, et al. Coordination of tumor growth and host wasting by tumor-derived Upd3. Cell Rep. 2021;36(7):109553.
Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science. 2003;302(5648):1227-1231.
Hodgson JA, Parvy JP, Yu Y, Vidal M, Cordero JB. Drosophila Larval models of invasive tumorigenesis for in vivo studies on tumour/peripheral host tissue interactions during cancer cachexia. Int J Mol Sci. 2021;22(15):8317.
Hirabayashi S, Baranski TJ, Cagan RL. Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. Cell. 2013;154(3):664-675.
Lodge W, Zavortink M, Golenkina S, et al. Tumor-derived MMPs regulate cachexia in a Drosophila cancer model. Dev Cell. 2021;56(18):2664-2680.e6.
Rosin D, Schejter E, Volk T, Shilo BZ. Apical accumulation of the Drosophila PDGF/VEGF receptor ligands provides a mechanism for triggering localized actin polymerization. Development. 2004;131(9):1939-1948.
Santabarbara-Ruiz P, Leopold P. An Oatp transporter-mediated steroid sink promotes tumor-induced cachexia in Drosophila. Dev Cell. 2021;56(19):2741-2751.e7.
Chen Y, Xu W, Chen Y, et al. Renal NF-kappaB activation impairs uric acid homeostasis to promote tumor-associated mortality independent of wasting. Immunity. 2022;55(9):1594-1608.e6.
Graca FA, Rai M, Hunt LC, et al. The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy. Nat Commun. 2022;13(1):2370.
Wang X, Li J, Zhang W, et al. IGFBP-3 promotes cachexia-associated lipid loss by suppressing insulin-like growth factor/insulin signaling. Chin Med J (Engl). 2023;136(8):974-985.
Costantini M, Testa S, Mozetic P, et al. Microfluidic-enhanced 3D bioprinting of aligned myoblast-laden hydrogels leads to functionally organized myofibers in vitro and in vivo. Biomaterials. 2017;131:98-110.
Aguilar-Agon KW, Capel AJ, Martin NRW, Player DJ, Lewis MP. Mechanical loading stimulates hypertrophy in tissue-engineered skeletal muscle: Molecular and phenotypic responses. J Cell Physiol. 2019;234(12):23547-23558.
Martin NRW, Aguilar-Agon K, Robinson GP, et al. Hypoxia Impairs Muscle Function and Reduces Myotube Size in Tissue Engineered Skeletal Muscle. J Cell Biochem. 2017;118(9):2599-2605.
Martin NRW, Turner MC, Farrington R, Player DJ, Lewis MP. Leucine elicits myotube hypertrophy and enhances maximal contractile force in tissue engineered skeletal muscle in vitro. J Cell Physiol. 2017;232(10):2788-2797.
Vandenburgh H, Del Tatto M, Shansky J, et al. Attenuation of skeletal muscle wasting with recombinant human growth hormone secreted from a tissue-engineered bioartificial muscle. Hum Gene Ther. 1998;9(17):2555-2564.
Mudera V, Smith AS, Brady MA, Lewis MP. The effect of cell density on the maturation and contractile ability of muscle derived cells in a 3D tissue-engineered skeletal muscle model and determination of the cellular and mechanical stimuli required for the synthesis of a postural phenotype. J Cell Physiol. 2010;225(3):646-653.
Gholobova D, Gerard M, Terrie L, et al. Coculture method to obtain endothelial networks within human tissue-engineered skeletal muscle. Methods Mol Biol. 2019;1889:169-183.
Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45(10):2215-2229.
Powell C, Shansky J, Del Tatto M, et al. Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum Gene Ther. 1999;10(4):565-577.
Vandenburgh H. High-content drug screening with engineered musculoskeletal tissues. Tissue Eng Part B Rev. 2010;16(1):55-64.
Vandenburgh H, Shansky J, Benesch-Lee F, et al. Drug-screening platform based on the contractility of tissue-engineered muscle. Muscle Nerve. 2008;37(4):438-447.
Vandenburgh H, Shansky J, Benesch-Lee F, et al. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. Faseb J. 2009;23(10):3325-3334.
Yang J, Zhang Z, Zhang Y, et al. ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-regulated release of extracellular vesicles from cancer cells. Gastroenterology. 2019;156(3):722-734.e6.
Russell ST, Tisdale MJ. The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer. 2005;92(5):876-881.
Bing C, Trayhurn P. New insights into adipose tissue atrophy in cancer cachexia. Proc Nutr Soc. 2009;68(4):385-392.
Batista Jr ML, Peres SB, McDonald ME, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine. 2012;57(1):9-16.
Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat Rev Cancer. 2017;17(12):751-765.
Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479-497.
Tomasin R, Martin A, Cominetti MR. Metastasis and cachexia: alongside in clinics, but not so in animal models. J Cachexia Sarcopenia Muscle. 2019;10(6):1183-1194.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
京公网安备11010802044758号